Vaccination Against SARS-CoV-2 Protects from Morbidity, Mortality and Sequelae from COVID19 in Patients with Cancer

Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined.

Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients.

Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320).

Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.

Citing Articles

SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico.

Barrientos-Flores C, Vilar-Compte D, Martinez-Rivera N, Villasenor-Echavarri R, Martin-Onraet A Vaccines (Basel). 2024; 12(10).

PMID: 39460329 PMC: 11512203. DOI: 10.3390/vaccines12101163.

Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain.

Lazar Neto F, Mercade-Besora N, Raventos B, Perez-Crespo L, Castro Junior G, Ranzani O Nat Commun. 2024; 15(1):5088.

PMID: 38898035 PMC: 11187152. DOI: 10.1038/s41467-024-49285-y.

Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach.

Calcaterra V, Zanelli S, Foppiani A, Verduci E, Benatti B, Bollina R Diseases. 2024; 12(5).

PMID: 38785750 PMC: 11120262. DOI: 10.3390/diseases12050095.

Definition and measurement of post-COVID-19 conditions in real-world practice: a global systematic literature review.

Yang J, Markus K, Andersen K, Rudolph A, McGrath L, Nguyen J BMJ Open. 2024; 14(1):e077886.

PMID: 38233057 PMC: 10806676. DOI: 10.1136/bmjopen-2023-077886.

COVID-19 vaccine hesitancy: assessing the prevalence, predictors, and effectiveness of a community pharmacy based counseling intervention.

Kiptoo J, Isiiko J, Yadesa T, Rhodah T, Alele P, Mulogo E BMC Public Health. 2024; 24(1):111.

PMID: 38184570 PMC: 10771691. DOI: 10.1186/s12889-023-17532-4.

References

Pinato D, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R . Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020; . PMC: 7668225. DOI: 10.1158/2159-8290.CD-20-0773. View

Addeo A, Shah P, Bordry N, Hudson R, Albracht B, Di Marco M . Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021; 39(8):1091-1098.e2. PMC: 8218532. DOI: 10.1016/j.ccell.2021.06.009. View

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

Pinato D, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A . Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer. 2021; 150:190-202. PMC: 8023206. DOI: 10.1016/j.ejca.2021.03.035. View

Araf Y, Akter F, Tang Y, Fatemi R, Parvez M, Zheng C . Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022; 94(5):1825-1832. PMC: 9015557. DOI: 10.1002/jmv.27588. View

Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L . Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2022; 2(12):1321-1337. DOI: 10.1038/s43018-021-00275-9. View

Becerril-Gaitan A, Vaca-Cartagena B, Ferrigno A, Mesa-Chavez F, Barrientos-Gutierrez T, Tagliamento M . Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2021; 160:243-260. PMC: 8548030. DOI: 10.1016/j.ejca.2021.10.014. View

Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah M . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276-280. DOI: 10.1038/s41586-021-03777-9. View

Pinato D, Tabernero J, Bower M, Scotti L, Patel M, Colomba E . Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021; 22(12):1669-1680. PMC: 8565932. DOI: 10.1016/S1470-2045(21)00573-8. View

10.

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

11.

Garassino M, Whisenant J, Huang L, Trama A, Torri V, Agustoni F . COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020; 21(7):914-922. PMC: 7292610. DOI: 10.1016/S1470-2045(20)30314-4. View

12.

Pinato D, Lee A, Biello F, Segui E, Aguilar-Company J, Carbo A . Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel). 2020; 12(7). PMC: 7408670. DOI: 10.3390/cancers12071841. View

13.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View

14.

Schmidt A, Labaki C, Hsu C, Bakouny Z, Balanchivadze N, Berg S . COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2021; 33(3):340-346. PMC: 8704021. DOI: 10.1016/j.annonc.2021.12.006. View

15.

Jones D, Neal R, Duffy S, Scott S, Whitaker K, Brain K . Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020; 21(6):748-750. PMC: 7251992. DOI: 10.1016/S1470-2045(20)30242-4. View

16.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

17.

Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M . Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2020; 384(1):80-82. PMC: 7727324. DOI: 10.1056/NEJMc2032195. View

18.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

19.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

20.

Hoffmann M, Kruger N, Schulz S, Cossmann A, Rocha C, Kempf A . The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022; 185(3):447-456.e11. PMC: 8702401. DOI: 10.1016/j.cell.2021.12.032. View